Atea Pharmaceuticals Inc Stock

$3.49

2.24% yesterday

Nasdaq, Jul 16, 10:00 pm CET

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Atea Pharmaceuticals Inc Stock price

$3.49

-26.85 88.50% 5Y

Nasdaq, Closing price Wed, Jul 16 2025

-0.08 2.24%

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$298.7m

Enterprise Value

$-126.8m

Net debt

positive

Cash

$425.4m

Shares outstanding

85.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

1.0

P/B

0.7

Financial Health

Equity Ratio

94.5%

Return on Equity

-38.3%

ROCE

-33.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-139.6m | $-157.2m

EBIT

$-140.0m | $-216.2m

Net Income

$-140.0m | $-246.2m

Free Cash Flow

$-126.1m

EPS

$-1.7

FCF per Share

$-1.5

Short interest

4.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Atea Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Atea Pharmaceuticals Inc forecast:

3x Hold

38%

4x Sell

50%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Atea Pharmaceuticals Inc forecast:

Buy

13%

Hold

38%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Atea Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	46 46	7% 7% -
- Research and Development Expense	93 93	35% 35% -
EBITDA	-140 -140	17% 17% -
- Depreciation and Amortization	0.42 0.42	0% 0% -
EBIT (Operating Income) EBIT	-140 -140	17% 17% -
Net Profit	-140 -140	14% 14% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Atea Pharmaceuticals Inc Stock News

Neutral

GlobeNewsWire

●

23 days ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada

Neutral

GlobeNewsWire

●

2 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Sup porting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14 , 2...

Neutral

GlobeNewsWire

●

2 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Needed in Phase 1 Stu...

More Atea Pharmaceuticals Inc News

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Head office	United States
CEO	Jean-Pierre Sommadossi
Employees	75
Founded	2012
Website	ateapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now